Embracing change, Fostering growth
2015 FT-Deloitte US Healthcare Conference
The healthcare and life sciences industry is facing a time of both tumultuous change and momentous opportunity. In the U.S., healthcare reform has reached a new level of maturity and is beginning to transform the landscape of the industry for life sciences companies, payers, providers and patients.
The Financial Times U.S. Healthcare & Life Sciences Conference
On May 6, 2015, Deloitte was proud to once again be the lead sponsor of the Financial Times U.S. Healthcare and Life Sciences Conference, one of America's pre-eminent industry events which was attended by almost 200 leading executives, government decision makers, investors, analysts and other specialist providers.
Video recordings from all the sessions at the 2015 conference are now available. Review the recordings to hear the debates around topics such as value-based pricing, cyber security, M&A, aging, and much more. Additionally, Deloitte leaders share their perspectives on topics addressed at this year's conference. View their videos below:
- Pete Mooney, DTTL Life Sciences and Health Care Industry Leader, discusses how life sciences M&A activity is changing, the role of transactions in a company’s strategy, and the types of transactions the sector can expect in the future. WATCH VIDEO
- Ellen Stafford-Sigg, Principal, Deloitte Consulting LLP, discusses how information will have the biggest impact on changing the health care ecosystem. WATCH VIDEO
- Homi Kapadia, Deloitte U.S. Life Sciences Sector Leader, discusses the impact value-based care will have on life sciences companies as they bring new products and innovations to market. WATCH VIDEO
- Jennifer Malatesta, Deloitte U.S. Life Sciences Advisory Leader, discusses the opportunity for pharma companies to leverage digital health and the biggest risk they could face in doing so. WATCH VIDEO
Deloitte leaders share perspectives from FT USHC Conference
Leaders from Deloitte's life sciences and health care practice share their perspectives on some of the topics discussed at the 2015 Financial Times U.S. Healthcare and Life Sciences Conference that was held on May 6, 2015.
The future of health care
The Predictions 2020 report is based on an observation of trends, events, and bold steps that, if accelerated over the next five years and beyond, paint a picture of a very different vision of health care in 2020.
The Affordable Care Act has disrupted the US health care market. Discover how out of this disruption may emerge an open, consumer-driven health care ecosystem focused on transparency, actionable insights, collaboration, and engagement may emerge.
Value-based pricing and reimbursement
The Life Sciences Executive Series explores how CEOs should evaluate value-based care as an opportunity to develop deeper relationships with payer and provider customers through collaborations such as shared accountability models.
The market shift toward value-based care continues to move along with increasing speed in hope that it will bend the curve on cost and improve quality.
Value-based payment models for health care have the potential to upend traditional patient care and business models. Explore what an organization do to effectively make the shift?
The Deloitte 2014 Survey of U.S. Physicians examines current and expected levels of VBC engagement by physicians, and details what resources and skills physicians think could help put them on a path to success.
M&A and beyond
Collaborations and partnerships among industry peers, companies large and small; academic centers; foundations; and new players outside the health care sector are gaining favor.
The Economist Intelligence Unit, in collaboration with Deloitte Touche Tohmatsu Limited, surveyed 240+ senior life sciences and health care executives for their insights into the forces underlying the current M&A trends in the life sciences and health care industry.
M&A can help medical technology companies overcome growth challenges and capitalize on opportunities within a relatively short timeframe.
Homi Kapadia & Pete Mooney explore how M&A and alternative arrangements are impacting the global life sciences and health care industry and what do the ‘bets’ new entrants are placing in the industry tell us about where future growth may come from.
This survey report focuses on the post-merger integration phase of the merger & acquisition lifecycle, sharing the views of 800+ executives on what drives successes and what foils deals.
Digital health and cyber security
Greg Reh, DTTL Global Life Sceinces leader, and Jennifer Malatesta, Deloitte U.S. Life Sciences Advisory leader, explore how the digital health revolution is impacted by cyber security challenges and concerns.
Patients are understandably anxious, if not downright fearful, about how their personal medical data is handled and shared, yet health care transformation is contingent on earning their trust.
This article discuss the areas that companies should consider in tightening up their safeguards against intellectual property theft.
Recent guidance issued by the U.S. Food and Drug Administration (FDA) has put the security of medical devices back in the spotlight. Explore what corporate leaders should consider.
Greg Reh discusses how wearable devices can make a meaningful impact on patient-centered health care and demonstrate a clear return on investment.
Health Care Current: Insights to keep you informed and ahead
This weekly series explores breaking news and developments in the U.S. health care industry, examines key issues facing life sciences and health care companies and provides updates and insights on policy, regulatory and legislative changes.